Medtronic plc (NYSE:MDT) has analysts on the Bullish side this week.

September 8, 2018 - By Megan Stone

Medtronic plc (NYSE:MDT) LogoInvestors sentiment increased to 1.08 in Q1 2018. Its up 0.06, from 1.02 in 2017Q4. It increased, as 80 investors sold Medtronic plc shares while 383 reduced holdings. 88 funds opened positions while 414 raised stakes. 1.04 billion shares or 0.00% more from 1.04 billion shares in 2017Q4 were reported.
Endurant Capital Mngmt Lp holds 4.05% of its portfolio in Medtronic plc (NYSE:MDT) for 135,115 shares. Greystone Managed Investments holds 0.36% or 104,925 shares in its portfolio. Ruggie Cap Gru owns 95 shares. 1,663 are owned by Blue Chip. Prudential Pcl holds 10,138 shares. National Bank & Trust Of Mellon Corporation reported 14.13M shares stake. White Pine Ltd Liability Corp reported 2,787 shares or 0.08% of all its holdings. New Mexico Educational Retirement Board holds 0.39% of its portfolio in Medtronic plc (NYSE:MDT) for 128,987 shares. Chemung Canal Com stated it has 32,238 shares. Regent Management Ltd holds 0.12% or 4,400 shares. Monarch Capital Mgmt reported 83,042 shares. Roberts Glore And Il has 7,153 shares. Naples Ltd Liability Corp holds 0.65% or 27,283 shares in its portfolio. Invesco Limited invested in 0.24% or 8.04M shares. Envestnet Asset Incorporated owns 174,715 shares or 0.04% of their US portfolio.

Medtronic plc (NYSE:MDT) Ratings Coverage

Among 12 analysts covering Medtronic (NYSE:MDT), 7 have Buy rating, 0 Sell and 5 Hold. Therefore 58% are positive. Medtronic had 17 analyst reports since March 29, 2018 according to SRatingsIntel. As per Thursday, May 24, the company rating was maintained by Bank of America. Stifel Nicolaus maintained the stock with “Hold” rating in Wednesday, August 22 report. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, August 22. Bank of America maintained Medtronic plc (NYSE:MDT) rating on Wednesday, June 6. Bank of America has “Buy” rating and $9800 target. The firm has “Market Perform” rating by William Blair given on Wednesday, June 6. The firm earned “Buy” rating on Monday, August 27 by Argus Research. Morgan Stanley maintained Medtronic plc (NYSE:MDT) rating on Thursday, March 29. Morgan Stanley has “Equal-Weight” rating and $90 target. Morgan Stanley maintained Medtronic plc (NYSE:MDT) rating on Wednesday, August 22. Morgan Stanley has “Equal-Weight” rating and $105 target. As per Friday, April 27, the company rating was initiated by Piper Jaffray. Wells Fargo maintained the stock with “Market Perform” rating in Wednesday, August 22 report. Below is a list of Medtronic plc (NYSE:MDT) latest ratings and price target changes.

27/08/2018 Broker: Argus Research Old Rating: Buy New Rating: Buy Old Target: $95 New Target: $108 Maintain
24/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $104 New Target: $109 Maintain
22/08/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $98 New Target: $105 Maintain
22/08/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $94 New Target: $104 Maintain
22/08/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Market Perform Old Target: $95 New Target: $101 Maintain
22/08/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $87 New Target: $96 Maintain
22/08/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $95 New Target: $105 Maintain
13/08/2018 Broker: Needham Old Rating: Buy New Rating: Strong Buy Old Target: $103 New Target: $119 Upgrade
27/06/2018 Broker: Bernstein Rating: Market Perform New Target: $88 Initiates Coverage On
06/06/2018 Broker: Bank of America Rating: Buy New Target: $98.0000 Maintain

The stock decreased 0.18% or $0.17 during the last trading session, reaching $96.32. About 5.66M shares traded or 21.11% up from the average. Medtronic plc (NYSE:MDT) has risen 0.84% since September 8, 2017 and is uptrending. It has underperformed by 11.73% the S&P500.

Medtronic plc manufactures and sells device medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company has market cap of $130.08 billion. The companyÂ’s Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It has a 41.54 P/E ratio. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases.

Another recent and important Medtronic plc (NYSE:MDT) news was published by Seekingalpha.com which published an article titled: “Premarket analyst action – healthcare” on August 27, 2018.

Medtronic plc (NYSE:MDT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.